TC-5619: Phase II started

Targacept began a double-blind, placebo-controlled, parallel-group, U.S. Phase II trial to evaluate 1, 5 and 25 mg oral TC-5619 given once daily for 12 weeks in 125 patients. AstraZeneca has an option...